Coronary disease & ACSSecondary analysis
Ticagrelor vs Clopidogrel in Clopidogrel-Naive Patients With Chronic Coronary Syndrome
- Secondary analysis of the ALPHEUS randomised trial
- prespecified analysis
Authors' conclusion
Clopidogrel-naive patients presented less periprocedural complications compared to clopidogrel(+) patients, a difference related to a lower risk profile and less complex PCI.
Study context
- Population
- Patients undergoing elective percutaneous coronary intervention (PCI)
- Participants
- 1,882 patients
- Comparison
- clopidogrel(+) vs clopidogrel(-)
- clopidogrel(+)n = 805reference
- Primary endpoint
- Composite of:
- PCI-related MI
- Major injury (third and fourth universal definition)
- Follow-up
- 48 hours after PCI
Primary result
PCI-related MI or major injury
Odds ratio
0.73
95% CI 0.60–0.88
By group
clopidogrel(-) vs clopidogrel(+)
OR 0.73 (95% CI 0.60–0.88)
As reported in the abstract
Further findings
Death, MI, stroke or TIA · 48 hours or 30 days
- No significant differences between clopidogrel(-) and clopidogrel(+)
Original publication
Ticagrelor vs Clopidogrel in Clopidogrel-Naive Patients With Chronic Coronary Syndrome. JACC Cardiovasc Interv. Published 5 June 2024. doi:10.1016/j.jcin.2024.04.015
Summarised from the published abstract; every number is checked against it